Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 1996Antimicrobial Agents and ChemotherapyOpen Access

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLütfiye MülazımoğluMarmara UniversitySDS D DrenningMarmara UniversityVYV L YuMarmara University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mülazımoğlu et al. (1996) studied this question.

synapsesocial.com/papers/6a8291ae342cda0577239a53https://doi.org/10.1128/aac.40.10.2428
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents1996 · 462 citations
  2. 2Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds1988 · 63 citations
  3. 3In vitro activity of the new fluoroquinolone CP-99,2191994 · 94 citations
  4. 4Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-566201986 · 21 citations
  5. 5In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms1993 · 110 citations